Form Approved OMB No. 0920-1385 Exp. Date: 3/31/26

_____ Patient demographic characteristics Unique patient ID: _____ (site_###) Site submitting case: _____ Location of residence for patient (ZIP Code): _____ OR [] Unknown Age at diagnosis (years): Sex: [] Male [] Female Race and/or ethnicity (select all that apply and enter additional details in the spaces provided): [] American Indian or Alaska Native Enter, for example, Navajo Nation, Blackfeet Tribe of the Blackfeet Indian Reservation of Montana, Native Village of Barrow Inupiat Traditional Government, Nome Eskimo Community, Aztec, Maya, etc. [] Asian - provide details below [] Chinese [] Asian Indian [] Filipino [] Vietnamese [] Korean [] Japanese Enter, for example, Pakistani, Hmong, Afghan, etc. [] Black or African American – provide details below [] African American [] Jamaican [] Haitian [] Nigerian [] Ethiopian [] Somali Enter, for example, Trinidadian and Tobagonian, Ghanaian, Congolese, etc. [] Hispanic or Latino – provide details below [] Mexican [] Puerto Rican [] Salvadoran [] Cuban [] Dominican [] Guatemalan Enter, for example, Colombian, Honduran, Spaniard, etc. Middle Eastern or North African - provide details below

Case report form: Chromoblastomycosis in the United States

CDC estimates the average public reporting burden for this collection of information as 30 minutes per response, including the time for reviewing instructions, searching existing data/information sources, gathering and maintaining the data/information needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR CDC/ATSDR Information Collection Review Office, 1600 Clifton Road NE, MS H21-8, Atlanta, Georgia 30333; ATTN: PRA (0920-1385).

| [] Lebanese [] Iranian [] Egyptian [] Syrian [] Iraqi Enter, for example, Moroccan, Yemeni, Kurdish, etc. | [] Israeli |
|---|--------------------------|
| [] Native Hawaiian or Pacific Islander – provide details below | |
| [] Native Hawaiian [] Samoan [] Chamorro [] Tongan Enter, for example, Chuukese, Palauan, Tahitian, etc. | [] Fijian [] Marshallese |
| [] White – provide details below | |
| [] English [] German [] Irish [] Italian [] Polish [] So Enter, for example, French, Swedish, Norwegian, etc. | cottish |
| | |
| Monthly household income (USD) | |
| Occupation at time of presumed infection: | |
| Industry at time of presumed infection: | |
| Underlying medical conditions (active or present in the 2 years before | e symptom onset) |
| Diabetes mellitus [] Yes [] No [] Unknown | |
| Chronic kidney disease [] Yes [] No [] Unknown If yes, on dialysis? [] Yes [] No [] Unknown If yes, GFR < 60? [] Yes [] No | |
| Liver cirrhosis? [] Yes [] No [] Unknown Chronic hepatitis without cirrhosis? [] Yes [] No [] Unknown If yes, [] Hep B [] Hep C | |
| Immunocompromising condition [] Yes [] No [] Unknown [] HIV infection [] HIV infection without AIDS (CD4 ≥ 200) [] HIV infection with AIDS (CD4 < 200) or chart diagnos [] Cancer diagnosis, specify [] On chemotherapy, specify Date of cancer diagnosis (mm/dd/yyyy): | |
| [] Solid organ, specify organ | |

| [] Hematologic (stem cell) Date of transplantation (mm/dd/yyyy): [] Immunosuppressive therapy, specify [] Other immunocompromised condition, specify | | | | | |
|--|--|--|--|--|--|
| Other major underlying condition not listed (specify): ============================== | | | | | |
| Exposure history | | | | | |
| Has patient traveled or lived internationally in their life? [] Yes [] No [] Unknown | | | | | |
| O Country 1; Approximate duration of stay (years): O Country 2; Approximate duration of stay (years): O Country 3; Approximate duration of stay (years): O Country 4; Approximate duration of stay (years): O Country 5; Approximate duration of stay (years): | | | | | |
| Did the patient immigrate to the United States? [] Yes [] No [] Unknown | | | | | |
| If yes, date of immigration (mm/dd/yyyy):[] Unknown | | | | | |
| If yes, country immigrated from: [] Unknown | | | | | |
| Any traumatic inoculation recalled? [] Yes [] No [] Unknown | | | | | |
| If yes, please describe geographic location (e.g., city, state): | | | | | |
| If yes, please describe the material involved (e.g., thorns, branches): | | | | | |
| If yes, please describe any weather events (e.g., hurricane, flood): | | | | | |
| If yes, please indicate approximate date of traumatic inoculation (mm/dd/yyyy): | | | | | |
| Most likely source of infection, according to clinician | | | | | |
| | | | | | |
| Diagnosis | | | | | |
| Did patient have health care facility visits (health center, hospital, etc.) for mycetoma symptoms before visit with mycetoma diagnosis? [] Yes [] No [] Unknown | | | | | |
| If yes, how many visits? | | | | | |
| Were there misdiagnoses before being diagnosed with mycetoma [] Yes [] No [] Unknown | | | | | |
| What misdiagnoses, if any, did this patient have before being diagnosed with mycetoma (in the last 12 months): • Please list all misdiagnoses: | | | | | |

Laboratory testing (associated with diagnosis):

| [] Dermoscopy [] Not performed [] Unknown in date of procedure: | formed [] Unknown if peesult: Inknown if performed ; result: In if performed | |
|---|---|----------------------------------|
| date of collection (mm/dd/yyyy): Organism(s): | | gative: |
| [] Broad range sequencing [] Not performed [] | | |
| date of collection (mm/dd/yyyy): | · | 8s, ITS): |
| Positive/Negative: Or | | |
| Signs and symptoms noted in medical chart: | | |
| Signs & Symptoms | Yes/No | Onset Date |
| Warty lesions | | |
| Raised and crusted lesions | | |
| Tumors | | |
| Infiltrative plaques | | |
| Nodules | | |
| Polymorphic lesions | | |
| Migraines | | |
| Pain | | |
| Itching | | |
| Edema | | |
| Syncope Vomiting | | |
| Other symptoms, please describe: | | |
| Please indicate the specific location(s) of the kapply): | oody of the chromoblast | omycosis lesions (check all that |
| [] Head and neck | | |
| [] Trunk | | |
| [] Upper limbs | | |
| [] Buttocks, perineum, genitals | | |
| [] Lower limbs | | |

| Disease severity: | | | | | | | |
|------------------------------------|-------------------------|--------------|---------------------------|----------------|----------------|--------------------------------|--------------|
| [] Mild (solitary p | laque or noc | lule less th | nan 5 cm in dia | ameter) | | | |
| [] Moderate (sing diameter, and in | - | | | - | olaque morphol | ogy, less than 15 c | m in |
| [] Severe (extens | ive involvem | ent of adja | acent or nona | djacent skin a | reas) | | |
| Did mycetoma ca | ause any forn | n of disabi | lity: [] Yes [] N | lo [] Unknown | 1 | | |
| If yes, please fill o | out the table | below: | | | | | |
| Dis | Disability | | Yes/No | Onset Date | | Number of days with disability | |
| Inability to walk | | | | | | | |
| Impacts mobilit | y/ability to w | /alk | | | | | |
| Inability to worl | < | | | | | | |
| | | | | | | | |
| Treatment | | | | | | | |
| Was the patient i | treated for cl [] No | nromoblas | stomycosis? [] Unknown | [] Missing | /Not document | ed | |
| If yes, lis steroids) in the ta | - | utic agents | s (e.g., antifun | gals, immune | response modu | ulators, antibiotics | , |
| Therapeutic | Max Daily | Route | Start Date | Duration | Therapy | Discontinued | Therapeutic |
| Agent Name | dose | (e.g., IV, | | of Therapy | ongoing | due to toxicity. I | _ |
| | (mg/day) | PO, IT) | | | at time of | yes, describe | Monitoring |
| | | | | | abstraction | toxicity | (e.g., serum |
| | | | | | | | level of |
| | | | | | | | antifungal) |
| | | | , , | 1 | | [] Yes [] No | [] Yes [] No |
| | | | ├ _′′ | days | [] Yes [] No | | Level 1: |
| | | | | | | | Date: |
| | | | | | | | Value: |
| | | | | | | | Taide: |
| | | | | | | | Level 2: |
| | | | | | | | Date: |
| | | | | | | | Value |

_days

[] Yes [] No

[] Yes [] No

[] Yes [] No

Level 1:

Additional comments on anatomical location:

| | | | | | | Date: |
|--|----|------|--------|--------|------------------|-----------------|
| | | | | | | Value: |
| | | | | | | |
| | | | | | | Level 2: |
| | | | | | | Date: |
| | | | | | | Value |
| | | | | | | [] Yes [] No |
| | // | days | [] Yes | [] No | [] 103 [] 110 | [] 163 [] 140 |
| | | uays | [] 103 | [] 140 | | Level 1: |
| | | | | | | Date: |
| | | | | | | |
| | | | | | | Value: |
| | | | | | | |
| | | | | | | Level 2: |
| | | | | | | Date: |
| | | | | | | Value |
| | | | | | [] Yes [] No | [] Yes [] No |
| | // | days | [] Yes | [] No | | |
| | | | | | | Level 1: |
| | | | | | | Date: |
| | | | | | | Value: |
| | | | | | | |
| | | | | | | Level 2: |
| | | | | | | Date: |
| | | | | | | Value |
| | | | | | | [] Yes [] No |
| | // | days | [] Yes | [] No | [] 103 [] 110 | [] 163 [] 140 |
| | | uays | [] 103 | [] 140 | | Level 1: |
| | | | | | | |
| | | | | | | Date: |
| | | | | | | Value: |
| | | | | | | |
| | | | | | | Level 2: |
| | | | | | | Date: |
| | | | | | | Value |
| | | | | | [] Yes [] No | [] Yes [] No |
| | // | days | [] Yes | [] No | | |
| | | | | | | Level 1: |
| | | | | | | Date: |
| | | | | | | Value: |
| | | | | | | |
| | | | | | | Level 2: |
| | | | | | | Date: |
| | | | | | | Value |
| | | | | | | T alac |

| Notes about treatment: | | |
|------------------------|--|--|
| | | |
| | | |

| Did the patient undergo surgical excision If yes, date of surgical excision | | | : [] Yes [] No [] Unknown | | |
|---|---------------------|----------------------------|---------------------------|--|--|
| Did the patient have cryotherapy: [] Yes [] No [] Unknown | | | | | |
| Did the patient have heat therapy: [] | Yes [] No [] Unkn | own | | | |
| Did the patient have light-based then | apy: [] Yes [] No [|] Unknown | | | |
| | | ======= | | | |
| Complications: | | | | | |
| Outcome | Yes/No | Onset Date | Notes (e.g., location) | | |
| Tissue fibrosis | | | | | |
| Secondary bacterial infection | | | | | |
| Squamous cell carcinoma | | | | | |
| Internal organ involvement | | | | | |
| Amputation | | | | | |
| Lymphedema | | | | | |
| Did the chromoblastomycosis infecti | | | | | |
| If yes, what was the date of one the exception of atrophic sca | | • • • | eous manifestations with | | |
| If no, what was date of last follow-up (mm/dd/yyyy): | | | | | |
| Did this patient die within 2 years aft | er the chromobla | stomycosis diagnosis? [] | Yes [] No [] Unknown | | |
| If yes, was chromoblastomyo Unknown | cosis a contributin | g factor in patient's deat | h? [] Yes [] No [] | | |
| Additional comments: | | | | | |
| | | | | | |
| Annendiy 2: Dermatology Life Quali | ty Index Tool | | | | |

Appendix 2: Dermatology Life Quality Index Tool

Dermatology Life Quality Index Questionnaire:

- 1. Over the last week, how itchy, sore, painful, or stinging has your skin problem been?
 - a. Very much
 - b. A lot
 - c. A little
 - d. Not at all
- 2. Over the last week, how embarrassed or self-conscious have you been because of your skin problem?

- a. Very much
 b. A lot
 c. A little
 d. Not at all
 ver the last week,
- 3. Over the last week, how much has your skin problem interfered with you going shopping or looking after your home or garden?
 - a. Very much
 - b. A lot
 - c. A little
 - d. Not at all
 - e. Not relevant
- 4. Over the last week, how much has your skin problem influenced the clothes you wear?
 - a. Very much
 - b. A lot
 - c. A little
 - d. Not at all
 - e. Not relevant
- 5. Over the last week, how much has your skin problem affected any social or leisure activities?
 - a. Very much
 - b. A lot
 - c. A little
 - d. Not at all
 - e. Not relevant
- 6. Over the last week, how much has your skin problem made it difficult for your to do any sport?
 - a. Very much
 - b. A lot
 - c. A little
 - d. Not at all
 - e. Not relevant
- 7. Over the last week, has your skin problem prevented you from working of studying
 - a. Yes
 - b. No
 - c. Not relevant
 - i. If no, over the last week how much has your skin problem been a problem at work or studying?
 - 1. A lot
 - 2. A little
 - 3. Not at all
- 8. Over the last week, how much has your skin problem created problems with your partner or any of your close friends or relatives?
 - a. Very much
 - b. A lot
 - c. A little
 - d. Not at all

- e. Not relevant
- 9. Over the last week, how much has your skin problem caused any sexual difficulties?
 - a. Very much
 - b. A lot
 - c. A little
 - d. Not at all
 - e. Not relevant
- 10. Over the last week, how much of a problem has the treatment for your skin problem been, for example by making your home messy, or by taking up time?
 - a. Very much
 - b. A lot
 - c. A little
 - d. Not at all
 - e. Not relevant